This changed with preliminary studies suggesting that sorafenib, an oral multikinase inhibitor of serine-threonine kinases Raf-1 and B-Raf and the receptor tyrosine kinase inhibitor (TKI) of VEGFRs-1, 2, and 3 and platelet-derived growth factor receptor beta (PDGFR-beta), may be therapeutically effective for HCC given the kinases’ role in cellular signaling implicated in the molecular pathogenesis of HCC [12]. Here, RAF1 is linked to hepatocellular carcinoma.